Guidelines for the Management of Deep Mycosis in Neutropenic Patients
スポンサーリンク
概要
- 論文の詳細を見る
Invasive fungal infections (IFIs) are a major cause of morbidity and mortality in neutropenic patients with leukemia and those undergoing hematopoietic stem cell transplant (HSCT). Two major IFIs are systemic candidiasis (including candidemia, chronic disseminated candidiasis and pneumonia) and invasive pulmonary aspergillosis. Recently, the incidence of the latter has been increasing. Three levels of diagnosis are specified in the Japanese guidelines for the diagnosis and treatment of IFIs. Proven fungal infections are diagnosed by histological/microbiological evidence of fungi at the site of infection or positive blood culture (fungemia). Clinically documented fungal infections are diagnosed by typical radiological findings such as halo sign on chest CT plus positive serological/molecular evidence of fungi such as Aspergillus galactomannan, β-glucan or fungal DNA. Possible fungal infections are diagnosed by typical radiological findings or positive serological/molecular evidence of fungi. For patients with high risk such as those undergoing HSCT, antifungal prophylaxis using oral antifungal agents is recommended. For possible fungal infections, empiric therapy with fluconazole (FLCZ) or amphotericin B (AMPH) is recommended. For patients with proven fungal infections or clinically documented fungal infections, targeted therapy is warranted. In case of candidemia, the best choice is FLCZ (400mg/day) or AMPH (0.5∼0.7mg/kg/day), and for invasive pulmonary aspergillosis, a higher dose of AMPH (1.0∼1.5mg/kg/day) is indicated. Micafungin (MCFG), recently licensed in Japan, is an active agent for both Candida and Aspergillus. This drug seems useful for empiric and targeted therapy of IFIs.
- 日本医真菌学会の論文
日本医真菌学会 | 論文
- (1→3)-β-D-グルカン測定の問題点と進歩
- 両側の肺空洞病変にアスペルギルス感染を合併し抗真菌薬, ミカファンギンとイトラコナゾールの併用療法が有効であった Wegener 肉芽腫症の一例
- Trichophyton tonsurans 臨床分離株に対する各種抗真菌薬の in vitro 抗真菌活性
- 爪白癬の治療について : 日本医真菌学会標準化委員会提案2007
- Candida 属菌種のアゾール系薬感受性試験における現行の日本医真菌学会法, およびその改変法とNCCLS M27-A2法との相関性に関する検討